Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $62.3 million.

  • Relay Therapeutics' Total Liabilities fell 3173.89% to $62.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.3 million, marking a year-over-year decrease of 3173.89%. This contributed to the annual value of $93.5 million for FY2024, which is 166.02% up from last year.
  • Relay Therapeutics' Total Liabilities amounted to $62.3 million in Q3 2025, which was down 3173.89% from $63.2 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Total Liabilities registered a high of $168.9 million during Q3 2022, and its lowest value of $38.6 million during Q1 2021.
  • Its 5-year average for Total Liabilities is $104.4 million, with a median of $95.9 million in 2021.
  • Within the past 5 years, the most significant YoY rise in Relay Therapeutics' Total Liabilities was 20281.09% (2021), while the steepest drop was 8094.4% (2021).
  • Relay Therapeutics' Total Liabilities (Quarter) stood at $110.6 million in 2021, then surged by 35.18% to $149.6 million in 2022, then tumbled by 38.5% to $92.0 million in 2023, then grew by 1.66% to $93.5 million in 2024, then tumbled by 33.38% to $62.3 million in 2025.
  • Its last three reported values are $62.3 million in Q3 2025, $63.2 million for Q2 2025, and $78.3 million during Q1 2025.